Home/Filings/4/A/0001213900-24-030963
4/A//SEC Filing

Marques Tiago 4/A

Accession 0001213900-24-030963

CIK 0001841330other

Filed

Apr 4, 8:00 PM ET

Accepted

Apr 5, 9:45 PM ET

Size

8.9 KB

Accession

0001213900-24-030963

Insider Transaction Report

Form 4/AAmended
Period: 2024-03-01
Marques Tiago
DirectorChief Executive Officer
Transactions
  • Award

    Stock Option (right to buy)

    2024-03-01+15,00015,000 total
    Exercise: $8.13Exp: 2034-02-28Common Stock (15,000 underlying)
  • Award

    Stock Option (right to buy)

    2024-03-01+11,66911,669 total
    Exercise: $8.13Exp: 2034-02-28Common Stock (11,669 underlying)
Footnotes (3)
  • [F1]The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.
  • [F2]The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date.
  • [F3]The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024.

Documents

1 file

Issuer

Pasithea Therapeutics Corp.

CIK 0001841330

Entity typeother

Related Parties

1
  • filerCIK 0001875240

Filing Metadata

Form type
4/A
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 9:45 PM ET
Size
8.9 KB